Review Article
Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers
Table 2
MicroRNAs as potential biomarkers for BTC.
| | miRNA (source) | Groups | Clinicopathological characteristics associated with deregulated miRNA expression | AUC | Ref. |
| Downregulated | 106a (serum) | CC versus control | Lymph node metastasis; poor prognosis | 0.89 | [91] | 106a (serum) | CC versus BBD | | 0.79 | [91] | 1537 (bile) | PSC versus PSC/CC | 0.78 | [92] | 412 (bile) | 0.81 | [92] | 640 (bile) | 0.81 | [92] | 3189 (bile) | 0.80 | [92] |
| Upregulated | 21 (plasma) | BTC versus control | Decline of miRNA-21 plasma levels after surgery | 0.93 | [93] | 21 (plasma) | BTC versus BBD | | 0.83 | [93] | 150 (plasma) | IHC versus control | 0.791; 0.920 (+CA19-9) | [26] | 21 (tissue) | CC versus control | 0.995 | [83] | 21 (tissue) | IHC versus control | Decline of miRNA-21 serum levels after potentially curative surgery | 0.908 | [84] | 26a (serum) | CC versus control | Decline of miRNA-26a serum levels after potentially curative surgery; shorter progression-free and overall survival | 0.899 | [94] | 483-5p (serum) | | 0.77; 0.81 (+miRNA 194) | [95] | 194 (serum) | 0.74; 0.81 (+miRNA 483-5p) | [95] | 192 (serum) | Lymph node metastasis; shorter survival | 0.803 | [96] | 200c (serum) | PSC versus control | | 0.74 | [95] | 1281 (serum) | PSC versus CC | 0.83 | [92] | 126 (serum) | 0.87 | [92] | 26a (serum) | 0.78 | [92] | 30b (serum) | 0.78 | [92] | 122 (serum) | 0.65 | [92] | 9 (bile) | BTC versus BBD | 0.975 | [97] | 145 (bile) | 0.975 | [97] | 944 (bile) | 0.765 | [97] | 21 (urine) | CC versus control | | 0.820; 0.849 (+miRNA 192) | [98] | 192 (urine) | | 0.682; 0.849 (+miRNA 192) | [98] |
|
|
AUC: area under curve; BBD: benign biliary diseases; BTC: biliary tract cancer; CC: cholangiocarcinoma; IHC: intrahepatic cholangiocarcinoma; miRNA: microRNA; PSC: primary sclerosing cholangitis; PSC/CC: cholangiocarcinoma complicating primary sclerosing cholangitis.
|